What Sionna Therapeutics, Inc. told the SEC could break it.

Proposed CMS most-favored-nation pricing models (GLOBE for Part B, GUARD for Part D) and IRA provisions would impose international-benchmark rebates on single-source drugs and sole-source biologics, pressuring future pricing.

“the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS's spending and eligibility criteria.”

Sionna's use of foreign CROs/CDMOs (including in China) is exposed to geopolitical shifts, U.S. trade/sanctions changes, and restrictions on transferring health/genetic data to countries of concern.

“our use of foreign CROs and CDMOs, including those located in China, may be subject to unanticipated changes in the geopolitical landscape that could have negative impacts on our business operations.”

Sionna has generated no product revenue, posted a $75.3M FY2025 net loss and a $256.4M accumulated deficit, and does not expect product approval for at least several years, if ever.

“We have not generated any revenue from product sales or other sources. Due to our significant research, development and manufacturing expenditures, we have accumulated substantial losses and negative cash flows since our inception, including net losses of $75.3 million and $61.7 million for the years ended December 31, 2025”

Sionna owns no manufacturing facilities and relies entirely on third-party manufacturers for clinical and (planned) commercial supply of its product candidates.

“We have leveraged multiple third-party manufacturers to support the manufacturing of our product candidates for clinical trials and, if we receive regulatory approval, we intend to rely on third parties for commercial manufacture. We do not own or operate, and currently have no plans to establish, any manufacturing facilities.”